Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil (DR-COP) in Aggressive Non-Hodgkin's Lymphoma
NCT00184002Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Jan 2003
- Primary completion
- Dec 2012
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in non-Hodgkin lymphoma (NHL), sponsored by University of Southern California. Started Jan 2003; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00184002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184002.